Avanafil

Active ingredient description

Avanafil is a highly selective and potent, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5. When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by avanafil produces increased levels of cGMP in the corpus cavernosum of the penis. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
G04BE10
G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BE Drugs used in erectile dysfunction
Discover more medicines within G04BE10

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
SPEDRA Tablet
Summary of Product Characteristics (SPC)

Medicines

Avanafil is the active ingredient of these drugs:

Drug
Countries
ANIME

Ecuador

SPEDRA

Australia Austria Cyprus Estonia Finland

STENDRA

Turkey United States

VIBRALKANA

Ecuador

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₂₃H₂₆ClN₇O₃
Molecular mass: 483.951 g/mol

External identifiers

CAS Substance: 330784-47-9
DrugBank Drug: DB06237
KEGG Drug: D03217
PubChem Compound: 9869929
RxNorm Ingredient: 1291301
SNOMED-CT Concept: 703956007
Avanafil (substance)
UNII Identifier: DR5S136IVO
AVANAFIL
 
Next: Usage >